Recent Quotes
My Watchlist
Indicators
EL&P Market Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Savara, Inc. - Common Stock (NQ:SVRA)

5.270 +0.040 (+0.76%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,002,912
Open 5.230
Bid (Size) 5.000 (5,800)
Ask (Size) 5.500 (1,000)
Prev. Close 5.230
Today's Range 5.100 - 5.435
52wk Range 1.890 - 7.005
Shares Outstanding 114,066,080
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Savara Announces Participation in Upcoming Investor Healthcare Conferences
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Amendment to Hercules Capital Debt Facility Providing up to $75M of Additional Debt Funding Upon U.S. Food and Drug Administration (FDA) Approval of MOLBREEVI*
From Savara Inc.
Via Business Wire

Performance

YTD
-6.6%
-6.6%
1 Month
-8.7%
-8.7%
3 Month
+21.7%
+21.7%
6 Month
+104.3%
+104.3%
1 Year
+88.9%
+88.9%

More News

Read More
News headline image
SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Savara Announces New Employment Inducement Grant
From Savara Inc.
Via Business Wire
News headline image
PANTHERx® Rare Selected by Savara as the U.S. Exclusive Specialty Pharmacy for MOLBREEVI*
From Savara Inc.
Via Business Wire
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Savara Resubmits the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference
From Savara Inc.
Via Business Wire
News headline image
Savara Announces European Patent Office (EPO) Intends to Grant a Patent for the Liquid Formulation of MOLBREEVI*
From Savara Inc.
Via Business Wire
News headline image
Savara and PARI Granted a European Patent Covering the Drug-Device Combination of MOLBREEVI* Delivered Via the Proprietary eFlow® Nebulizer System
From Savara Inc.
Via Business Wire
News headline image
Savara Announces Participation in Upcoming Investor Healthcare Conferences
From Savara Inc.
Via Business Wire
News headline image
Savara Reports Third Quarter 2025 Financial Results and Provides Business Update
From Savara Inc.
Via Business Wire
News headline image
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Class Action Filed Against Savara Inc. (SVRA) - November 7, 2025 Deadline to Join - Contact Levi & Korsinsky
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Deadline Soon: Savara Inc. (SVRA) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
From The Law Offices of Frank R. Cruz
Via Business Wire
News headline image
SAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Savara Stockholders to Contact the Firm Before November 7th
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Faruqi & Faruqi, LLP Examining Potential Securities Law Violations at Savara
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm
From Schall Law
Via GlobeNewswire
News headline image
November 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SVRA
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
November 7, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against SVRA
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
Investors Who Lost Money on Savara Inc. (SVRA) Should Contact Levi & Korsinsky About Pending Class Action - SVRA
Via NewMediaWire
Topics Fraud Lawsuit
News headline image
Investors Who Lost Money on Savara Inc. (SVRA) Should Contact Levi & Korsinsky About Pending Class Action - SVRA
Via TheNewswire.com
Topics Fraud Lawsuit
News headline image
SAVARA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urgently Reminds Savara Stockholders to Contact the Firm Before November 7th
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Lost Money on Savara Inc. (SVRA)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky
Via NewMediaWire
Topics Fraud Lawsuit

Frequently Asked Questions

Is Savara, Inc. - Common Stock publicly traded?
Yes, Savara, Inc. - Common Stock is publicly traded.
What exchange does Savara, Inc. - Common Stock trade on?
Savara, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Savara, Inc. - Common Stock?
The ticker symbol for Savara, Inc. - Common Stock is SVRA on the Nasdaq Stock Market
What is the current price of Savara, Inc. - Common Stock?
The current price of Savara, Inc. - Common Stock is 5.270
When was Savara, Inc. - Common Stock last traded?
The last trade of Savara, Inc. - Common Stock was at 02/10/26 04:00 PM ET
What is the market capitalization of Savara, Inc. - Common Stock?
The market capitalization of Savara, Inc. - Common Stock is 601.13M
How many shares of Savara, Inc. - Common Stock are outstanding?
Savara, Inc. - Common Stock has 601M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.